Non-alcoholic fatty liver DISEASE (NAFLD) is the most common chronic liver disease in
Western countries and affects approximately 25% of the adult population. Since NAFLD is …

Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD) are both
manifestations of end-organ damage of the metabolic syndrome. Through multiple …

Background & Aims Cardiovascular disease remains the leading cause of death in patients
with nonalcoholic fatty liver disease (NAFLD). Studies examining the association of coronary …

A growing body of evidence is pointing out the pathophysiological role of fat accumulation in
different organs. Ectopic fat depots within heart, liver, skeletal muscle, kidney, and pancreas …

In clinical practice, combined heart and liver dysfunctions coexist in the setting of the main
heart and liver diseases because of complex cardiohepatic interactions. It is becoming …

Abstract Purpose of Review Patients with non-alcoholic fatty liver disease (NAFLD), often
considered as the hepatic manifestation of the metabolic syndrome, represent a population …

Non-alcoholic fatty liver disease (NAFLD) is the main cause of liver diseases in Spain and
the incidence is raising due to the outbreak of type 2 diabetes and obesity. This CPG …

In recent years, a wealth of studies has identified various molecular species released by
cardiac muscle under physiological and pathological conditions that exert local paracrine …

Atrial fibrillation (AF) and venous thromboembolism (VTE) are highly prevalent and relevant
healthcare issues. Direct oral anticoagulants (DOACs) are now the first-choice for …

Nonalcoholic fatty liver disease (NAFLD), also named metabolic dysfunction-associated fatty
liver disease (MAFLD), is a progressive disease spectrum encompassing simple steatosis …